104 related articles for article (PubMed ID: 23953882)
21. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
22. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
[TBL] [Abstract][Full Text] [Related]
23. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T; Haines P; Stayner LA; McGill S; Wang L; Piekarz R; Wong T; Siu LL; Espinoza-Delgado I; Holleran JL; Egorin MJ; Yee KW
Leuk Lymphoma; 2015; 56(10):2793-802. PubMed ID: 25682963
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Liesveld JL; O'Dwyer K; Walker A; Becker MW; Ifthikharuddin JJ; Mulford D; Chen R; Bechelli J; Rosell K; Minhajuddin M; Jordan CT; Phillips GL
Leuk Res; 2013 Dec; 37(12):1622-7. PubMed ID: 24138944
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
28. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
29. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
30. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
31. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
33. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
37. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
